Albis Francesco Gabrielli

Dr. Albis Francesco Gabrielli

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2022 in Vaccine
Verified
Journal Article
Open access
KMKurayi Mahachi
Kurayi Mahachi
JKJoss Kessels
Joss Kessels
KBKofi Boateng
Kofi Boateng
ABAnne Eudes Jean Baptiste
Anne Eudes Jean Baptiste
PMPamela Mitula
Pamela Mitula
AGAlbis Francesco Gabrielli
Albis Francesco Gabrielli
• Comprehensive review of recent literature on zero- or missed-dose children in Nigeria. • Risk factors are well-known and widely studied. • Literature on interventions was scattered, and focussed on campaigns and polio. • Gaps exist in investigating how to deliver sustainable immunization programs. • Further work is needed to operationalise findings of this review.

7 August 2012 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
FVFidel Villegas
Fidel Villegas
RARené Angles
René Angles
RBRené Barrientos
René Barrientos
GBGary Barrios
Gary Barrios
M. Adela ValeroM. Adela Valero
M. Adela Valero
AGAlbis Francesco Gabrielli
Albis Francesco Gabrielli
The Bolivian northern Altiplano is characterized by a high prevalence of Fasciola hepatica infection. In order to assess the feasibility, safety and efficacy of large-scale administration of triclabendazole as an appropriate public health measure to control morbidity associated with fascioliasis, a pilot intervention was implemented in 2008. Schoolchildren from an endemic community were screened for fascioliasis and treated with a single administration of triclabendazole (10 mg/kg). Interviews to assess the occurrence of adverse events were conducted on treatment day, one week later, and one month after treatment. Further parasitological screenings were performed three months after treatment and again two months later (following a further treatment) in order to evaluate the efficacy of the intervention. Ninety infected children were administered triclabendazole. Adverse events were infrequent and mild. No serious adverse events were reported. Observed cure rates were 77.8% after one treatment and 97.8% after two treatments, while egg reduction rates ranged between 74% and 90.3% after one treatment, and between 84.2% and 99.9% after two treatments. The proportion of high-intensity infections (≥400 epg) decreased from 7.8% to 1.1% after one treatment and to 0% after two treatments. Administration of triclabendazole is a feasible, safe and efficacious public health intervention in an endemic community in the Bolivian Altiplano, suggesting that preventive chemotherapy can be applied to control of fascioliasis. Further investigations are needed to define the most appropriate frequency of treatment. Fascioliasis is highly prevalent in the northern Altiplano of Bolivia. We wanted to ascertain whether a preventive chemotherapy approach, involving the large-scale distribution of triclabendazole within endemic communities, would be feasible for controlling morbidity associated with this disease. Consequently, we implemented a pilot intervention among schoolchildren in a community near Lake Titicaca and assessed this intervention's safety (by evaluating the occurrence of adverse events following treatment) and its efficacy (by measuring changes in prevalence and intensity of infection). Adverse events on treatment day, and one week and one month later were infrequent and mild, and no serious adverse events were reported. We observed cure rates of 77.8% after one treatment and 97.8% after two treatments, egg reduction rates of 74–90.3% after one treatment and 84.2–99.9% after two treatments, and a decrease in the proportion of high-intensity infections (≥400 epg) from 7.8% to 1.1% after one treatment and to 0% after two treatments. We conclude that administration of triclabendazole is a safe and efficacious public health intervention for control of fascioliasis in an endemic community in the Bolivian Altiplano. Preventive chemotherapy with triclabendazole, without individual-level diagnosis and treatment, appears therefore as a feasible option. However, further investigation is needed to define the most appropriate frequency of treatment.

29 July 2010 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AKArtemis Koukounari
Artemis Koukounari
CDChristl A Donnelly
Christl A Donnelly
MSMoussa Sacko
Moussa Sacko
AKAdama D Keita
Adama D Keita
ALAly Landouré
Aly Landouré
JWJoanne P Webster
Joanne P Webster
In the developing world co-infections and polyparasitism within humans appear to be the rule rather than the exception, be it any combination of inter-specific and/or inter- and intra-Genera mixed infections. Mixed infections might generate synergistic or antagonistic interactions and thereby clinically affect individuals and/or impact parasite epidemiology.

1 October 2006 in Acta Tropica
Verified
Journal Article
Closed access
AGAlbis Francesco Gabrielli
Albis Francesco Gabrielli
STSeydou Touré
Seydou Touré
BSBertrand Sellin
Bertrand Sellin
ESElisabeth Sellin
Elisabeth Sellin
CKCésaire Ky
Césaire Ky
AFAlan Fenwick
Alan Fenwick

1 March 2017 in Acta Tropica
Verified
Journal Article
Closed access
AHAyat A. Haggag
Ayat A. Haggag
ARAmal Rabiee
Amal Rabiee
KEKhaled M. Abd Elaziz
Khaled M. Abd Elaziz
AGAlbis Francesco Gabrielli
Albis Francesco Gabrielli
RHRehab Abdel Hay
Rehab Abdel Hay
RRReda M.R. Ramzy
Reda M.R. Ramzy

24 April 2023 in Current Tropical Medicine Reports
Verified
Journal Article
Open access
PDF file
AGAlbis Francesco Gabrielli
Albis Francesco Gabrielli
ADAmadou Garba Djirmay
Amadou Garba Djirmay
Purposeof Review: The purpose of this review is to provide an overview of the burden of schistosomiasis in the European continent. It discusses three subjects: the endemic forms of non-human schistosomiasis in Europe; the introduction of transmission of human schistosomiasis into Europe; and the occurrence of imported cases of human schistosomiasis. Recent Findings: Europe is not endemic for human schistosomiasis; nevertheless, it is affected by the disease in multiple ways, although the magnitude of the burden remains elusive because of gaps in surveillance and reporting. Summary: Schistosomiasis is a global neglected disease prevalent in tropical and subtropical areas. As of 2022, it is estimated that 251 million people require preventive chemotherapy for schistosomiasis, 90% of whom live in Africa. In Europe, human schistosomiasis is frequently detected in migrants from endemic countries who reach the continent. Additionally, outbreaks due to local transmission can sporadically occur following the introduction of schistosomes in one of the many freshwater bodies in southern Europe where competent snail hosts are found. Finally, human cercarial dermatitis is frequently occurring in Europe, because of the presence of avian schistosomiasis in several countries across the continent. A stronger epidemiological surveillance and reporting system, coupled with more surveys on humans and snails, can contribute to better assess and characterize the burden of schistosomiasis in Europe.